Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
57
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,110.40 | 155.50 | 1.74% |
| CAC 40 | 8,177.89 | 157.58 | 1.96% |
| DAX 40 | 26,437.67 | 573.05 | 2.22% |
| Dow JONES (US) | 53,356.12 | 1,569.40 | 3.03% |
| FTSE 100 | 10,829.21 | 190.78 | 1.79% |
| HKSE | 23,919.50 | 393.53 | 1.67% |
| NASDAQ | 25,736.51 | 364.50 | 1.44% |
| Nikkei 225 | 62,423.55 | 234.92 | 0.38% |
| NZX 50 Index | 14,028.69 | 245.24 | 1.78% |
| S&P 500 | 7,688.62 | 119.70 | 1.58% |
| S&P/ASX 200 | 8,974.40 | 139.90 | 1.58% |
| SSE Composite Index | 3,686.17 | 78.07 | 2.16% |